When should we conduct surveillance for cardiac dysfunction in cancer survivors?
Abstract
No abstract availableKeywords
Funding Information
- Chief Scientist Office (National Health Service (NHS) Research Scotland (N)
This publication has 8 references indexed in Scilit:
- Surveillance of left ventricular function among cancer survivorsHeart, 2025
- Cardiovascular disease and cancer: shared risk factors and mechanismsNature Reviews Cardiology, 2024
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- Statins and Left Ventricular Ejection Fraction Following Doxorubicin TreatmentNEJM Evidence, 2022
- Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and MetoprololCirculation, 2021
- Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databasesThe Lancet, 2019
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the CommunityCirculation, 2003